UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 16, 2017

 

ARCH THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   000-54986   46-0524102
(State or other jurisdiction   (Commission   (I.R.S. Employer
of incorporation)   File Number)   Identification No.)

 

235 Walnut Street, Suite 6  
Framingham, Massachusetts 01702
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (617) 431-2313

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

Item 8.01    Other Events.

 

On February 16, 2017, Arch Therapeutics, Inc. (the “Company”) issued a press release announcing that it provided a corporate milestone update regarding its plans to file for regulatory approvals in the U.S. and Europe at the RHK Capital 2017 Disruptive Growth & Healthcare Conference in New York City. The text of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

 

Item 9.01    Financial Statements and Exhibit

 

(d) Exhibits

 

Exhibit   Description
99.1   Press Release issued by Arch Therapeutics, Inc. on February 16, 2017


 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

  ARCH THERAPEUTICS, INC.
   
Dated: February 16, 2017 By: /s/ Terrence W. Norchi, M.D.
  Name:  Terrence W. Norchi, M.D.
  Title: President, Chief Executive Officer

 

 

 

 

 

Exhibit List

 

Exhibit   Description
99.1   Press Release issued by Arch Therapeutics, Inc. on February 16, 2017